Miguel Méndez Ureña

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Enrique Aranda, Pilar García‐Alfonso, Manuel Benavides et al. · European Journal of Cancer · 2018 · 82 citations

Medicine, Oncology, Pharmacotherapy +16

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Jean‐François Emile, Catherine Julié, Karine Le Malicot et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Immunology, Oncology +17

Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Pilar Alfonso, Manuel Benavides, A. Ruiz et al. · Annals of Oncology · 2014 · 18 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer

G. Pérez Manga, Parham Khosravi Shahi, Miguel Méndez Ureña et al. · Breast Cancer · 2009 · 15 citations

Medicine, Oncology, Pharmacology +16